David Happel Sagimet Biosciences Inc. (SGMT) insider trading activity

SGMT Quotes by TradingView
Shares Held (Direct Ownership) 755K
18.15% 3M change
20.43% 12M change
Total Value Held N/A

David Happel Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 06 2025
BUY
Grant, award, or other acquisition
-
116,000 Added 13.31%
755,200 Series A Common Stock
Mar 26 2024
BUY
Open market or private purchase
$63,766 $5.27 p/Share
12,100 Added 1.86%
639,200 Series A Common Stock
Dec 07 2023
BUY
Open market or private purchase
$6,559 $4.1 p/Share
1,600 Added 0.25%
627,100 Series A Common Stock
Nov 17 2023
BUY
Grant, award, or other acquisition
-
624,910 Added 49.98%
625,500 Series A Common Stock
Nov 16 2023
BUY
Open market or private purchase
$1,386 $2.35 p/Share
590 Added 50.0%
590 Series A Common Stock

Also insider at

HZNP
Horizon Therapeutics Public Ltd Co Healthcare
EVP, Commercial Dev & Strategy
DH

David Happel

President & CEO
Dublin, L2

Track Institutional and Insider Activities on SGMT

Follow Sagimet Biosciences Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SGMT shares.

Notify only if

Insider Trading

Get notified when an Sagimet Biosciences Inc. insider buys or sells SGMT shares.

Notify only if

News

Receive news related to Sagimet Biosciences Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on SGMT